Company / PP&E (Net)
Haemonetics PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$284.1M
FY2025
5-year range
$217.6M / $311.4M
FY2021-FY2025
Trend
-8.8%
vs FY2024
Sector context
#63 of 135
Health Care
What the data says
At $284M, Haemonetics's pp&e (net) ranks #63 of 135 in the Health Care sector. PP&E (Net) has fluctuated over the past 10 years, ranging from $218M in FY2021 to $344M in FY2019.
Based on SEC 10-K filings.
$284M in FY2025 with a 5-year CAGR of +2.3%.
Declined from $311M to $284M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +3.2%
- 5-Year CAGR
- +2.3%
- 10-Year CAGR
- -
Sector benchmark
#63 of 135 in Health CareTop 47% of 135This company $284.1M Sector average $1.4B
▼
-79.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.3%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 8.8% year-over-year.
- Ranks #63 out of 135 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $284.1M | -8.8% |
| FY2024 | $311.4M | +0.2% |
| FY2023 | $310.9M | +20.3% |
| FY2022 | $258.5M | +18.8% |
| FY2021 | $217.6M | -14.1% |
| FY2020 | $253.4M | -26.3% |
| FY2019 | $344.0M | +3.6% |
| FY2018 | $332.2M | +2.6% |
| FY2017 | $323.9M | -4.1% |
| FY2016 | $337.6M | +4.9% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026